Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®)

Vaccine

Volumn 21, Issue 31, 2003, Pages 4588-4592

  Usonis, V ^a   Bakasenas V ^b   Valentelis, R ^b   Katiliene, G ^c   Vidzeniene, D ^c   Herzog, C ^d  

^a VILNIUS UNIVERSITY   (Lithuania)

^b Republican Immunisation Centre   (Lithuania)

^c Pylimo Out patient Clinic   (Lithuania)

^d Berna Biotech AG   (Switzerland)

Author keywords

Aluminium free vaccine; Epaxal ; Hepatitis A; Vaccine; Virosomes

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY TEMPERATURE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HEPATITIS A; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; NAUSEA; PAIN; PRIORITY JOURNAL; REVACCINATION; SIDE EFFECT; SINGLE DRUG DOSE; VACCINATION;

EID: 0142169004     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00509-7     Document Type: Article

References (19)

1. Koff R.S. Hepatitis A. Lancet. 351:1998;1643-1649.
2. Willner I.R., Uhl M.D., Howard S.C., Williams E.Q., Ricly C.A., Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann. Int. Med. 1998:1998;111-114.
3. World Health Organization. Weekly epidemiological record. Hepatitis A. Positioning paper. Wkly Epidemiol Rec 2000;5:37-44.
4. Barzaga N.G. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine. 18:2000;S61-S64.
5. Van Damme P. Hepatitis A: how to match prevention strategies to changing epidemiology. Vaccine. 19:2001;999-1002.
6. Loutan L., Bovier P., Althaus B., Glück R. Inactivated virosome hepatitis A vaccine. Lancet. 343:1994;322-324.
7. Just M., Berger R., Drechsler H., Brantschen S., Glück R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only 2 weeks. Vaccine. 10:1992;737-739.
8. Bovier P.A., Althaus B., Glueck R., Chippaux A., Loutan L. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J. Travel Med. 6:1999;228-233.
9. Glück R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine. 10:1992;915-919.
10. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(RR-12):1-38.
11. Troisi C.L., Hollinger F.B., Krause D.S., Pickering L.K. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules. Vaccine. 15:1997;1613-1617.
12. Piazza M., Safary A., Vegnente A.et al. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine. 17:1999;585-588.
13. Kanra G., Yalcin S.S., Ceyhan M., Yurdakök K. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk. J. Pediatr. 42:2000;105-108.
14. Linder N., Karetnyi Y., Gidony Y.et al. Decline of hepatitis A antibodies during the first 7 months of life in full-term and pre-term infants. Infection. 27:1999;128-131.
15. Dagan R., Amir J., Mijalovsky A.et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J. 19:2000;1045-1052.
16. Riedemann S., Reinhardt G., Frösner G., Glück R., Herzog C. Universal seroconvertion and low rate of side effects after one dose of the new hepatitis A vaccine EPAXAL, even when given to children less than 2 years of age. Schweiz Med. Wochenschr. 126(Suppl 74/II):1996;339.
17. Ambrosch F., Wiedermann G., Jonas S.et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine. 15:1997;1209-1213.
18. Chan C.Y., Lee S.D., Yu M.I., Wang Y.J., Chang F.Y., Lo K.W. Long-term follow-up of hepatitis A vaccination in children. Vaccine. 17:1999;369-372.
19. Bovier P.A., Bock J., Loutan L., Farinelli T., Glueck R., Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol. 68:2002;489-493.